Table 2.
Association of NRP1 transcript levels with patients’ clinicopathological data
| Variable | Number of cases | NRP1 high level | P-value |
|---|---|---|---|
| Age (years) | |||
| <50 | 21 (44%) | 11 | NS |
| ≥50 | 27 (56%) | 17 | |
| Body mass index (kg/m2) | |||
| 25–29 | 24 (50%) | 14 | NS |
| >29 | 22 (46%) | 13 | |
| Menopause status | |||
| Post | 37 (77%) | 21 | NS |
| Pre | 11 (23%) | 7 | |
| Stage | |||
| I | 11 (23%) | 4 | NS |
| II | 18 (37.5%) | 14 | |
| III | 16 (33%) | 6 | |
| IV | 3 (6.5%) | 2 | |
| Histological grade | |||
| I | 7 (14.5%) | 4 | NS |
| II | 25 (52%) | 15 | |
| III | 16 (33.5%) | 7 | |
| Mitotic rate | |||
| 1 | 19 (39.5%) | 10 | NS |
| 2 | 22 (46%) | 10 | |
| 3 | 7 (14.5%) | 6 | |
| Tumor size (cm) | |||
| ≤2 | 18 (37.5%) | 9 | NS |
| 2–5 | 22 (46%) | 12 | |
| ≥5 | 8 (16.5%) | 5 | |
| Lymph node involvement | |||
| Positive | 19 (39.5%) | 10 | NS |
| Negative | 29 (60.5%) | 16 | |
| HER2 | |||
| Positive | 25 (75%) | 16 | NS |
| Negative | 23 (25%) | 10 | |
| ER | |||
| Positive | 37 (77%) | 21 | NS |
| Negative | 11 (23%) | 5 | |
| PR | |||
| Positive | 35 (73%) | 19 | NS |
| Negative | 13 (27%) | 7 | |
| Breast cancer phenotype | |||
| Luminal A | 19 (39.5%) | 11 | 0.891 |
| Luminal B | 22 (46%) | 13 | |
| HER2 | 2 (4%) | 1 | |
| Triple negative | 5 (10.5%) | 3 |
Note: NRP1 high level was defined based on the cut-offs of the fold changes in tumoral tissue vs. the corresponding ANCT, and the median value of fold changes was set as cutoff.
Abbreviations: NRP1, neuropilin-1; ANCT, adjacent noncancerous tissue; HER2, human epidermal growth factor receptor 2; ER, estrogen receptor; PR, progesterone receptor; NS, not significant.